Ixekizumab: First Global Approval.
Ixekizumab (Taltz(®)) is a humanised monoclonal immunoglobulin G antibody developed by Eli Lilly and Company that has been approved in the USA as a treatment for plaque psoriasis. Ixekizumab is a specific inhibitor of interleukin-17A (IL-17A), a pro-inflammatory cytokine that has a role in the development of several inflammatory conditions. This article summarizes the milestones in the development of ixekizumab leading to this first approval for plaque psoriasis.
Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand. dru@adis.com.
Anthony
A
Markham
D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D017277:Drug Approval; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use; D020381:Interleukin-17 / Q000037:antagonists & inhibitors; D011565:Psoriasis / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D014481:United States; D014486:United States Food and Drug Administration
D061067:Antibodies, Monoclonal, Humanized; C508717:IL17A protein, human; D007074:Immunoglobulin G; D020381:Interleukin-17; C549079:ixekizumab